E-LIB Suche - Ergebnisse für: DeZern, Amy E.

1

SOHO State of the Art Updates and Next Questions: An Update..:

Hochman, Michael J. ; DeZern, Amy E.
Clinical Lymphoma Myeloma and Leukemia. , 2024

Link: https://doi.org/10.1016/..

2

Graft Failure Incidence, Risk Factors, and Outcomes in Pati..:

Mata, Jonaphine Rae ; Zahurak, Marianna ; Rosen, Natalie...
Transplantation and Cellular Therapy. , 2024

Link: https://doi.org/10.1016/..

3

The E592K variant of SF3B1 creates unique RNA missplicing a..:

Choi, In Young ; Ling, Jonathan P ; Zhang, Jian...
Blood Advances. , 2024

Link: https://doi.org/10.1182/..

4

Survey of Infection Surveillance, Prophylaxis, and Vaccinat..:

John, Tami ; Marón, Gabriela M. ; Abraham, Allistair...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S235 , 2024

Link: https://doi.org/10.1016/..

5

Engineering the best transplant outcome for high-risk acute..:

Belbachir, Safia ; Abraham, Allistair ; Sharma, Akshay...
Cytotherapy. 26 (2024) 6 - p. 546-555 , 2024

Link: https://doi.org/10.1016/..

6

Is there a path forward for immunotherapy in patients with ..:

Stahl, Maximilian ; DeZern, Amy E
The Lancet Haematology. 11 (2024) 1 - p. e5-e7 , 2024

Link: https://doi.org/10.1016/..

7

Toward a more patient‐centered drug development process in ..:

Efficace, Fabio ; Buckstein, Rena ; Abel, Gregory A....
HemaSphere. 8 (2024) 5 - p. , 2024

Link: https://doi.org/10.1002/..

8

Modified Delphi Panel Consensus Recommendations for Managem..:

Babushok, Daria V. ; DeZern, Amy E ; de Castro, Carlos...
Blood Advances. , 2024

Link: https://doi.org/10.1182/..

9

Oral decitabine–cedazuridine versus intravenous decitabine ..:

Garcia-Manero, Guillermo ; McCloskey, James ; Griffiths, Elizabeth A...
The Lancet Haematology. 11 (2024) 1 - p. e15-e26 , 2024

Link: https://doi.org/10.1016/..

10

POSTER: MDS-634 Efficacy and Safety of Oral Decitabine/Ceda..:

Savona, Michael R. ; McCloskey, James K. ; Griffiths, Elizabeth A....
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S186 , 2023

Link: https://doi.org/10.1016/..

11

Uniform conditioning regardless of donor in bone marrow tra..:

DeZern, Amy E. ; Zahurak, Marianna ; Jones, Richard J..
Haematologica. 109 (2023) 2 - p. 657-660 , 2023

Link: https://doi.org/10.3324/..

12

Reduced Intensity Conditioning Substituting Pentostatin for..:

Norman, Haval ; Porter, Timothy ; Ziggas, Jamie Elsner...
Transplantation and Cellular Therapy. 29 (2023) 2 - p. S97 , 2023

Link: https://doi.org/10.1016/..

13

Cell-free DNA measurable residual disease as a predictor of..:

Pasca, Sergiu ; Guo, Matthew Z. ; Wang, Shiyu...
Blood Advances. 7 (2023) 16 - p. 4660-4670 , 2023

Link: https://doi.org/10.1182/..

14

EXABS-119-MDS An Update on Higher Risk Myelodysplastic Synd..:

Hochman, Michael J. ; DeZern, Amy E.
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S21-S25 , 2023

Link: https://doi.org/10.1016/..

15

Combining PTCy and ATG for GvHD prophylaxis in non-malignan..:

DeZern, Amy E. ; Brodsky, Robert A.
Blood Reviews. 62 (2023) - p. 101016 , 2023

Link: https://doi.org/10.1016/..